Surmountable challenges in translating pigment epithelium-derived factor (PEDF) therapy from animal models to clinical trials for retinal degenerations.
Chader
Gerald J
GJ
The Doheny Retina Institute of the University of Southern California Medical School in Los Angeles, CA, USA.
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005136:Eye Proteins / Q000627:therapeutic use*; D006801:Humans; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012162:Retinal Degeneration / Q000188:drug therapy*; D015843:Serpins / Q000627:therapeutic use*; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D011480:Protease Inhibitors; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor